Overview

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status:
Withdrawn
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc